Involving disparate populations in clinical trials and biobanking protocols: experiences from the community network program centers.
Involving disparate populations in clinical trials and biobanking protocols: experiences from the community network program centers.
复制标题
DOI：
10.1158/1055-9965.epi-14-0118
复制
发表时间：
2014-03
期刊：
影响因子：
--
通讯作者：
Hébert JR
中科院分区：
文献类型：
--
作者：
Thompson B;Hébert JR
Underserved groups tend not to participate in a wide array of cancer research ranging from primary prevention to screening and treatment trials (1–5). With intensified focus on personalized medicine to target therapeutic recommendations, those groups who choose not to participate are left out of research aimed at developing exciting and potentially life-saving innovations (6–8). Furthermore, lack of participation in research limits the advances that occur as a result of clinical therapeutic and prevention trials (9, 10). To make significant progress in cancer prevention and control, it is necessary to engage members of high-risk groups, such as those affected by health disparities, in cancer research. This will require methods to increase participation in an array of prevention and treatment trials, perhaps with the explicit goal of improving designs so that trials are more appealing to the underserved groups (11). For personalized medicine, this requires providing biospecimens to understand gene–environment interactions that allows for some of the variability between populations in cancer incidence and mortality (12, 13).Research aimed at methods of cancer prevention and treatment requires at least two basic levels of commitment on the part of potential study participants. First, individuals must be willing to provide biospecimens to help answer important questions about the biologic causes of cancer (as well as other diseases). Second, individuals need to participate in prevention and therapeutic clinical trials designed to identify and quantify basic differences in biologic susceptibility and to assess the efficacy of medicines and devices that are developed. In both activities, therearedisparitiesinparticipation, withindividualsfrom many racial/ethnic minorities, as well as other underserved groups, being less likely to participate in either biospecimen donation and prevention or therapeutic trials. In this Focus issue, we discuss efforts made to better understand why members of underserved populations do not participate in biospecimen donation or in clinical trials, and strategies that have successfully engaged such groups
